Literature DB >> 9476646

hu-PBL-SCID mice: an in vivo model of Epstein-Barr virus-dependent lymphoproliferative disease.

M T Fuzzati-Armentero1, M A Duchosal.   

Abstract

The Epstein-Barr virus (EBV) exists in most humans as a lifelong latent infection established in host B cells after a primary viral encounter. In immunosuppressed individuals, such as post-transplant patients, the presence of EBV-infected B cells may lead to lymphoproliferative disease. Injection of human peripheral blood lymphocytes from EBV-positive donors into mice with severe combined immunodeficiency induces human lymphoproliferative disease in the recipient closely resembling that of human post-transplant patients. This xenochimeric human-mouse model is increasingly being used to elucidate the mechanisms of EBV-specific lymphomagenesis and to assess novel therapeutic approaches.

Entities:  

Mesh:

Year:  1998        PMID: 9476646     DOI: 10.14670/HH-13.155

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  3 in total

1.  The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.

Authors:  Alex S Hartlage; Tom Liu; John T Patton; Sabrina L Garman; Xiaoli Zhang; Habibe Kurt; Gerard Lozanski; Mark E Lustberg; Michael A Caligiuri; Robert A Baiocchi
Journal:  Cancer Immunol Res       Date:  2015-03-03       Impact factor: 11.151

2.  Fine-tuning the EBV+ hu-PBL-SCID xenogeneic chimera model using in vivo superinfection.

Authors:  K Kvell ; P Balogh ; P Németh
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.

Authors:  John T Patton; Mark E Lustberg; Gerard Lozanski; Sabrina L Garman; William H Towns; Callie M Drohan; Amy Lehman; Xiaoli Zhang; Brad Bolon; Li Pan; A Douglas Kinghorn; Michael R Grever; David M Lucas; Robert A Baiocchi
Journal:  Oncotarget       Date:  2015-02-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.